Discovery of C19-9 as a novel non-RGD inhibitor of αvβ3 to overcome enzalutamide resistance in castration-resistant prostate cancer

Signal Transduct Target Ther. 2023 Feb 10;8(1):60. doi: 10.1038/s41392-022-01236-z.

¹ Peking University First Hospital, Xishiku Street, Xicheng District, 100034, Beijing, China.
² School of Pharmaceutical Sciences, Peking University, Xueyuan Road 38, Haidian District, 100191, Beijing, China.
³ Institute of Materia Medica, Chinese Academy of Medical Sciences, Nanwei Road, Xicheng District, 100050, Beijing, China.
⁴ School of Pharmaceutical Sciences, Peking University, Xueyuan Road 38, Haidian District, 100191, Beijing, China. zmliu@bjmu.edu.cn.
⁵ Peking University First Hospital, Xishiku Street, Xicheng District, 100034, Beijing, China. cui.pharm@pkufh.com.

^# Contributed equally.

No abstract available

Publication types